1 . "Chronic kidney disease surveillance system, centers for disease control and prevention" . Prevalence and incidence [internet]. 2020 [cited 2021 April 20]. Available from: https://nccd.cdc.gov/ckd/TopicHome/PrevalenceIncidence.aspx

2 . McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. "Projecting ESRD Incidence and Prevalence in the United States through 2030" . J Am Soc Nephrol. 2019; 30(1):127–135.

3 . Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, et al.. "Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS)" . Eur J Vasc Endovasc Surg. 2018; 55(6):757–818.

4 . Port FK. "End-stage renal disease: magnitude of the problem, prognosis of future trends and possible solutions" . Kidney Int Suppl. 1995; 50:S3–6.

5 . Davidson I, Hackerman C, Kapadia A, Minhajuddib A. "Heparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit" . J Vasc Access. 2009; 10(3):153–6.

6 . Chandrashekar AR, Hoskatti CR, Desai SC, Prasad RB. "Role of Brachial Artery Ligation in Management of Prosthetic Arteriovenous Graft Infections" . Ann Vasc Surg. 2018; 48:75–78.

7 . Nassar GM, Ayus JC. "Infectious complications of the hemodialysis access" . Kidney Int. 2001; 60(1):1–13.

8 . Padberg FT, Calligaro KD, Sidawy AN. "Complications of arteriovenous hemodialysis access: recognition and management" . J Vasc Surg. 2008; 48(5 Suppl):55S–80S.

9 . Schwab DP, Taylor SM, Cull DL, Langan EM, Snyder BA, Sullivan TM, et al.. "Isolated arteriovenous dialysis access graft segment infection: the results of segmental bypass and partial graft excision" . Ann Vasc Surg. 2000; 14(1):63–6.

10 . Page M J, McKenzie J E, Bossuyt P M, Boutron I, Hoffmann T C, Mulrow C Det al.. "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews" . BMJ. 2021;372:n71

11 . Wells G, Shea B, O’Connell D, Peterson J, Welth V, Losos M, et al.. "The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses" , Ottawa Health Research Institute, Ottawa (ON), 2010.

12 . Deneuville M. "Infection of PTFE grafts used to create arteriovenous fistulas for hemodialysis access" . Ann Vasc Surg. 2000; 14(5):473–479.

13 . Kim SM, Min SK, Ahn S, Min SI, Ha J, Chung JK. "How to treat arteriovenous graft infection: total versus partial graft excision" . J Vasc Access. 2018; 19(2):125–130.

14 . Li YS, Feng PC, Ko PJ, Wei W, Yu SY, Kao TC, et al.. "Total Resection of Infected Peripheral Hemodialysis Grafts Has a Favorable Impact on Outcomes" . Ann Vasc Surg. 2021; 71:200–207.

15 . Schutte WP, Helmer SD, Salazar L, Smith JL. "Surgical treatment of infected prosthetic dialysis arteriovenous grafts: total versus partial graft excision" . Am J Surg. 2007; 193(3):385–388.

16 . Tabbara MR, O’Hara PJ, Hertzer NR, Krajewski LP, Beven EG. "Surgical management of infected PTFE hemodialysis grafts: analysis of a 15-year experience" . Ann Vasc Surg. 1995; 9(4):378–384.

17 . Walz P, Ladowski JS. "Partial excision of infected fistula results in increased patency at the cost of increased risk of recurrent infection" . Ann Vasc Surg. 2005; 19(1):84–89.

18 . Liu RH, Fraser CD, Zhou X, Beaulieu RJ, Reifsnyder T. "Complete versus partial excision of infected arteriovenous grafts: Does remnant graft material impact outcomes?" . J Vasc Surg. 2020; 71(1):174–179.

19 . Ryan SV, Calligaro KD, Scharff J, Dougherty MJ. "Management of infected prosthetic dialysis arteriovenous grafts" . J Vasc Surg. 2004; 39(1):73–78.

20 . Desai SS, Thompson P, Karydis N, Franchin M, White B, Tozzi M, et al.. "Arteriovenous Access Graft Infection: Standards of Reporting and Implications for Comparative Data Analysis" . Ann Vasc Surg. 2020; 63:391–398.

21 . Zibari GB, Rohr MS, Landreneau MD, Bridges RM, DeVault GA, Petty FH, et al.. "Complications from permanent hemodialysis vascular access" . Surgery. 1988; 104(4):681–6.

22 . Benrashid E, Youngwirth LM, Mureebe L, Lawson JH. "Operative and perioperative management of infected arteriovenous grafts" . J Vasc Access. 2017; 18(1):13–21.

23 . Akoh JA, Patel N. "Infection of hemodialysis arteriovenous grafts" . J Vasc Access. 2010; 11(2):155–8.

24 . Morimoto N, Tanabe M, Imono A, Otani M, Shioji S, Hirasawa S, et al.. "The utility of portable negative pressure wound therapy in the management of prosthetic dialysis arteriovenous graft infection" . J Vasc Access. 2020;1129729820927232.

25 . Cheng TW, Farber A, Eslami MH, Kalish JA, Jones DW, Rybin D, et al.. "Removal of infected arteriovenous grafts is morbid and many patients do not receive a new access within 1 year" . J Vasc Surg. 2019; 70(1):193–198.

26 . Palder SB, Kirkman RL, Whittemore AD, Hakim RM, Lazarus JM, Tilney NL. "Vascular access for hemodialysis. Patency rates and results of revision" . Ann Surg. 1985; 202(2):235–9.

27 . Anderson JE, Chang AS, Anstadt MP. "Polytetrafluoroethylene hemoaccess site infections" . ASAIO J. 2000; 46(6):S18–21.

28 . Fong IW, Capellan JM, Simbul M, Angel J. "Infection of arterio-venous fistulas created for chronic haemodialysis" . Scand J Infect Dis. 1993; 25(2):215–20.

29 . Sgroi MD, Kirkpatrick VE, Resnick KA, Williams RA, Wilson SE, Gordon IL. "Less Than Total Excision of Infected Prosthetic PTFE Graft Does Not Increase the Risk of Re-infection" . Vasc Endovascular Surg. 2015; 49(1-2):12–5.